REPL
Not the letter you want in your inbox
Replimune got a complete response letter from the FDA for RP1, its biologics license application in advanced melanoma. Translation: the agency isn’t ready to approve the drug, so the company has to go back, address the issues, and wait some more.
For investors, this is the biotech version of getting to the front door and realizing you forgot your keys. The company was pitching RP1 plus nivolumab as a meaningful shot at a major cancer market, and now the timeline just got shoved further into the future.
Why the market cares
Replimune is still in the clinical-stage bucket, which means the stock is basically a giant bet on future regulatory wins. A CRL tends to hit sentiment hard because it can:
- delay any potential launch
- raise questions about the data package or filing strategy
- force another round of spending with no immediate payoff
Big picture
This doesn’t necessarily mean the drug is dead. But it does mean the easy path to approval is gone, and for a biotech, that’s usually enough to send investors reaching for the antacid.